Literature DB >> 15009681

Effect of tissue transglutaminase on the solubility of proteins containing expanded polyglutamine repeats.

T-S Lai1, T Tucker, J R Burke, W J Strittmatter, C S Greenberg.   

Abstract

The expansion of a polyglutamine (polyQ) domain in neuronal proteins is the molecular genetic cause of at least eight neurodegenerative diseases. Proteins with a polyQ domain that is greater than 40 Q (Q40) residues form insoluble intranuclear and cytoplasmic inclusions. Expanded polyQ proteins self-associate by non-covalent interactions and become insoluble. They can also be covalently cross-linked by tissue transglutaminase (TTG), a calcium-dependent enzyme present in cells throughout the nervous system. However, it remains unclear whether TTG cross-linking directly contributes to the insolubility of the expanded polyQ proteins. Using an in vitro solubility assay, we found TTG cross-linked Q62 monomers into high molecular weight soluble complexes in a calcium-dependent reaction. Inhibition of TTG cross-linking by primary amine substrates including putrescine and biotinylated pentylamine antagonized TTG's ability to form soluble complexes. In contrast, primary amines (histamine and lysine) that were less effective inhibitors of TTG cross-linking did not inhibit Q62 from becoming insoluble. In summary, TTG can increase the solubility of expanded polyQ proteins by catalyzing intermolecular cross-links. This demonstrates directly that TTG will reduce the ability of expanded polyQ proteins from becoming insoluble. Furthermore, the effectiveness of a primary amine substrate at inhibiting formation of insoluble inclusions may be related to their ability to inhibit intermolecular cross-linking by TTG.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15009681     DOI: 10.1046/j.1471-4159.2003.02249.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  14 in total

Review 1.  γ-Glutamylamines and neurodegenerative diseases.

Authors:  Thomas M Jeitner; Kevin Battaile; Arthur J L Cooper
Journal:  Amino Acids       Date:  2012-03-10       Impact factor: 3.520

2.  Identification of chemical inhibitors to human tissue transglutaminase by screening existing drug libraries.

Authors:  Thung-S Lai; Yusha Liu; Tim Tucker; Kurt R Daniel; David C Sane; Eric Toone; James R Burke; Warren J Strittmatter; Charles S Greenberg
Journal:  Chem Biol       Date:  2008-09-22

Review 3.  Transglutaminase regulation of cell function.

Authors:  Richard L Eckert; Mari T Kaartinen; Maria Nurminskaya; Alexey M Belkin; Gozde Colak; Gail V W Johnson; Kapil Mehta
Journal:  Physiol Rev       Date:  2014-04       Impact factor: 37.312

Review 4.  Beyond the glutamine expansion: influence of posttranslational modifications of ataxin-1 in the pathogenesis of spinocerebellar ataxia type 1.

Authors:  Hyoungseok Ju; Hiroshi Kokubu; Janghoo Lim
Journal:  Mol Neurobiol       Date:  2014-04-22       Impact factor: 5.590

5.  Human tissue transglutaminase is inhibited by pharmacologic and chemical acetylation.

Authors:  Thung S Lai; Christopher Davies; Charles S Greenberg
Journal:  Protein Sci       Date:  2010-02       Impact factor: 6.725

6.  Physio-pathological roles of transglutaminase-catalyzed reactions.

Authors:  Mariangela Ricotta; Maura Iannuzzi; Giulia De Vivo; Vittorio Gentile
Journal:  World J Biol Chem       Date:  2010-05-26

7.  Beta-actin is a target for transglutaminase activity at synaptic endings in chicken telencephalic cell cultures.

Authors:  Lars Dolge; Karin Aufenvenne; Heiko Traupe; Werner Baumgartner
Journal:  J Mol Neurosci       Date:  2011-07-26       Impact factor: 3.444

8.  Tissue transglutaminase overexpression does not modify the disease phenotype of the R6/2 mouse model of Huntington's disease.

Authors:  Ashish Kumar; Andrew Kneynsberg; Janusz Tucholski; Giselle Perry; Thomas van Groen; Peter J Detloff; Mathieu Lesort
Journal:  Exp Neurol       Date:  2012-06-12       Impact factor: 5.330

Review 9.  Transglutaminases and neurodegeneration.

Authors:  Thomas M Jeitner; John T Pinto; Boris F Krasnikov; Mark Horswill; Arthur J L Cooper
Journal:  J Neurochem       Date:  2009-05       Impact factor: 5.372

10.  Dissecting the mechanisms of tissue transglutaminase-induced cross-linking of alpha-synuclein: implications for the pathogenesis of Parkinson disease.

Authors:  Adrien W Schmid; Diego Chiappe; Vérène Pignat; Valerie Grimminger; Ivan Hang; Marc Moniatte; Hilal A Lashuel
Journal:  J Biol Chem       Date:  2009-01-21       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.